Company intelligence / Profile preview

Structure Therapeutics

South San Francisco, California, United Statesstructuretx.gcs-web.com ↗

Ownership: Public · GPCR
Employees: ~163
Development stage: Phase 2

Overview

Structure Therapeutics has advanced multiple oral small molecule programs into clinical development. Its lead candidate GSBR‑1290 targets GLP‑1R for T2DM and obesity. Other programs include dual GLP‑1R/GIPR agonists and amylin agonists for metabolic diseases, as well as ANPA‑0073 and LTSE‑2578 for fibrotic lung diseases. The company’s approach aims to deliver biologic-like efficacy with the convenience of oral dosing[3][1].

Therapeutic areas: EndocrinologyPulmonology
Modalities: small molecules
Industry: Biotech

Drug pipeline

9 assets

aleniglipron

8 more assets in the full pipeline.

Request access →

Financials

Market cap: $2.3B
Total revenue: $0
Enterprise value: $988.1M

Beyond the preview

Go deeper on Structure Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Structure Therapeutics.

Explore the full profile